This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2021
Presentations
SGN-B6A | Solid Tumors | Abstract #2946
A First-In-Human Trial of the Integrin Beta-6-Targeted Antibody-Drug Conjugate, SGN-B6A, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)